Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSV Breakthrough Infections in Hospitalized Children After Immunoprophylaxis
TCTR20260311009Recruiting
- Sponsor
- Thai Red Cross Society
- Start
- Feb 2026
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Trial of nirsevimab and RSVpreF vaccine in respiratory syncytial virus disease (RSV), sponsored by Thai Red Cross Society. Primary endpoints: Clinical characterization of RSV breakthrough infections and Genotypic characterization of RSV strains. Started Feb 2026; status: recruiting.
02
Drugs
nirsevimabRSVpreF vaccine
03
Conditions
respiratory syncytial virus disease (RSV)
Beyond the preview
Go deeper on TCTR20260311009.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20260311009.